Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. - Wikidata - awgldk - TriplyDB

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

http://www.wikidata.org/entity/Q33658002

about

Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development Long-term effects of weight-reducing drugs in people with hypertension Long-term effects of weight-reducing drugs in hypertensive patients Cannabinoid type 1 receptor antagonists for smoking cessation Ventral Tegmental Area Afferents and Drug-Dependent Behaviors The New Era of Drug Therapy for Obesity: The Evidence and the Expectations Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy 50 years of hurdles and hope in anxiolytic drug discovery Antiobesity pharmacotherapy: new drugs and emerging targets Endocannabinoid signaling in the etiology and treatment of major depressive illness.Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis.Animal models to improve our understanding and treatment of suicidal behavior Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study.A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys Modelling cognitive affective biases in major depressive disorder using rodents.Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study p Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications.Incidence of cancer following bariatric surgery: systematic review and meta-analysis.Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels.Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction.The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications New targets to treat obesity and the metabolic syndrome.Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model.Neurobiological Interactions Between Stress and the Endocannabinoid System.Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review.Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?Significance of Kampo, Japanese traditional medicine, in the treatment of obesity: basic and clinical evidence.Stimulants for the Control of Hedonic Appetite.4-Year Cost Trajectories in Real-World Patients Matched to the Metabolic Profiles of Trial Subjects Before/After Treatment with Phentermine-Topiramate.Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression.Strategies for preventing type 2 diabetes: an update for clinicians.Interaction between interleukin-1β and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity.

P2860

Q22241480-F9C22627-F24C-4DD4-8375-F6D74FB344D8 Q24186054-BA1FF0C6-FD9A-465F-9A79-746F7D305A6D Q24200212-270764C4-D503-4562-8C9E-7DF8DA83DBD9 Q24235611-90053354-B3E9-492E-95BF-A2A63DADCBF8 Q26751118-25447C72-EF0A-4BE6-AB1C-A0EE1C3E107A Q26827555-2E8DB490-28C7-45CE-993E-28F2803FDA5D Q26851511-07071284-7518-43F6-9345-681E0546A372 Q27344569-F7C464FD-93CF-4A7C-9926-AE9A3DF1A8BA Q28078534-3F32FC0A-B69D-42DC-9B26-FEA561A23B1B Q28297569-AA8A6ED6-EB39-40E6-87D9-5017EFA7BC16 Q30354242-3594174A-78AE-47E7-A300-DB633862C4F2 Q30687668-4749AF9F-0522-4EAE-AEF2-35CF79815AE4 Q33572190-8289408F-F63B-4D75-AA4D-7AFA7D19DFB4 Q33631151-F771D8BE-75AB-4DE8-A206-2FAFE86968E7 Q33635653-9AF1451F-DC84-423F-9C8A-09D850EA9439 Q33818454-15C84281-9FAA-4365-A643-4B0D231D5FA9 Q34231426-4BEB2BB5-8C00-42D1-87BB-A9D7A1A85840 Q34349717-3175ED4A-2DD4-45E8-B5A9-C8B6AFAA6996 Q34538482-A832A653-7F0E-4CFD-8318-6DAD38B2BE42 Q35060314-3C871B34-A0DC-4745-AB8F-D87A999F2C2B Q35119719-ACEF13F8-51F8-4131-BD64-BAE0D5D0AF7F Q35122796-CC45E31C-3FF2-4F63-8508-CA3BE9AFA645 Q35166768-51709F6E-3BBD-4806-AB8E-CA01D24CE501 Q35849373-5A87848F-C8BB-438B-800F-32B3284E6ED3 Q35859738-D3EA74A7-0508-4733-9F45-D27FCCFA4A9E Q35951992-F0CF22CB-8B54-4256-A3C9-47C6EE6D293C Q36068914-1E4B4728-77E2-4EB3-B92D-7F48C3FB4DB8 Q36071373-7090A086-C2E6-4800-A02D-2DA6D7A53139 Q36366731-A07CDDDD-88C8-44DA-854D-28BA1F9E7927 Q36429054-E5B391F4-91B4-4E3D-8872-4D4E7C90AD57 Q36705836-86D8EAF1-FB66-43A9-9FF1-13B196BB3542 Q36789308-3F774F64-33B5-487D-A29D-F4C444425C62 Q36804810-186853CF-FCCC-4557-A696-38C0C873F47A Q36830567-4ADFC720-FCC4-41FC-BE69-5DC374B95EC4 Q36942815-E33A5BAF-E2C5-4D25-ABF1-2F4F54CF4C66 Q36996416-A1046E69-3A4F-4377-B7DA-8F11F6DE7D1C Q37117608-CDB1B6BA-6772-4C92-9251-8A2D299A5F7C Q37228420-30FE51AE-E343-4C71-8F57-2149D55BDB19 Q37279826-359D01FB-05AE-4613-9108-C219C56FA7B4 Q37337828-EB5E7425-4222-4770-9893-E0E0A02B2116

P2860

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

http://www.wikidata.org/entity/Q33658002

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Rimonabant for prevention of c ...... tre, placebo-controlled trial.

@ast

Rimonabant for prevention of c ...... tre, placebo-controlled trial.

@en

type

label

Rimonabant for prevention of c ...... tre, placebo-controlled trial.

@ast

Rimonabant for prevention of c ...... tre, placebo-controlled trial.

@en

prefLabel

Rimonabant for prevention of c ...... tre, placebo-controlled trial.

@ast

Rimonabant for prevention of c ...... tre, placebo-controlled trial.

@en

P1433

Q33658002-8EC72C59-7ED8-4FFF-849E-C2F42E2099FF

P1476

Q33658002-6AABC510-72F1-445C-AF15-A8949FBB2505

P2093

Q33658002-065588F9-1800-4A32-90A7-CD0615DCD76C

Q33658002-5B72FA94-A97F-4CC3-A940-11645E77B190

Q33658002-67D29B5D-8D43-42DE-B84C-4AA53814488A

Q33658002-69A5D43B-27B6-43CA-B69D-57B8369F4C10

Q33658002-7C6C0EF1-B8D0-47BC-9DE1-A7B61784FC1C

Q33658002-7EDD0ED2-BF60-4972-94E5-DB96A34F2809

Q33658002-9055A71E-2BC6-4434-9817-6E1693A06054

Q33658002-A8865494-BB8D-4CAD-AE85-FCB66A46CC77

Q33658002-B6AD2A9A-AF63-41C2-BA07-0D33D650CDE1

Q33658002-BAED39DD-D11D-4C52-B4CD-8908557BE02B

P304

Q33658002-C0D35284-1DBC-4A24-AEA8-61ED37B1A4F3

P31

Q33658002-EEA1D969-E0AF-4BC5-A9B9-BEA7D946E237

P356

Q33658002-8BB1A75E-7126-4ACE-AB3B-D195FDA1A424

P407

Q33658002-A43C0366-0EEF-4007-B394-E4BFF3A2A28D

P433

Q33658002-1CC474ED-4E4F-4A6A-8C9F-080E736F5A92

P478

Q33658002-0886D174-15F2-4F4A-AC5D-FD23FF93F357

P50

Q33658002-10CF27DA-8CB3-48A9-912F-1568C685350D

Q33658002-767D98B4-91FC-4604-A53E-302460C49644

Q33658002-B04FDD26-3E80-45AD-9C3F-ED22BE594BF2

Q33658002-F0DD7121-9D79-424A-897E-5ABA7A048F8D

P577

Q33658002-60C63383-0B05-4A0B-8D4A-444673F78471

P698

Q33658002-E49E5100-B264-4BF9-9908-D81C59035228

P921

Q33658002-1E67D124-01C2-4B4C-9C1B-E111C778CD6F

Q33658002-77B07037-A572-4B4C-9C95-B8B98C49A4B2

Q33658002-D02D8704-4FC2-46D2-831A-A6830241ED95

P356

S0140-6736(10)60935-X

P1433

P1476

Rimonabant for prevention of c ...... tre, placebo-controlled trial.

@en

P2093

Bernard Job

http://www.w3.org/2001/XMLSchema#string

CRESCENDO Investigators

http://www.w3.org/2001/XMLSchema#string

Christian W Hamm

http://www.w3.org/2001/XMLSchema#string

Christophe Gaudin

http://www.w3.org/2001/XMLSchema#string

Eric Cohen

http://www.w3.org/2001/XMLSchema#string

J Donald Easton

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Despres

http://www.w3.org/2001/XMLSchema#string

Judith H Murphy

http://www.w3.org/2001/XMLSchema#string

Keith A A Fox

http://www.w3.org/2001/XMLSchema#string

Mark A Creager

http://www.w3.org/2001/XMLSchema#string

P304

517-523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(10)60935-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

9740

http://www.w3.org/2001/XMLSchema#string

P478

376

http://www.w3.org/2001/XMLSchema#string

P50

Marie-Germaine Bousser

Gilles Montalescot

Deepak L. Bhatt

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20709233

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

multicenter trial